Resultados globales: 5 registros encontrados en 0.02 segundos.
Artículos, Encontrados 5 registros
Artículos Encontrados 5 registros  
1.
6 p, 916.0 KB Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma / De Mattos-Arruda, Leticia (Universitat Autònoma de Barcelona) ; Mayor, Regina (Vall d'Hebron Institut d'Oncologia) ; Ng, Charlotte K. Y. (Memorial Sloan Kettering Cancer Center) ; Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ; Martinez-Ricarte, Fran (Universitat Autònoma de Barcelona) ; Torrejon, Davis (Vall d'Hebron Institut d'Oncologia) ; Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Raventós, Carolina (Vall d'Hebron Institut d'Oncologia) ; Tang, Jiabin (Memorial Sloan Kettering Cancer Center) ; Guerini-Rocco, Elena (Memorial Sloan Kettering Cancer Center) ; Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Lois, Sergio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Marín, Oscar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; de la Cruz, Xavier (Institució Catalana de Recerca i Estudis Avançats) ; Piscuoglio, Salvatore (Memorial Sloan Kettering Cancer Center) ; Towers, Russel (Department of Surgery, Memorial Sloan Kettering Cancer Center) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona) ; Carles, Joan (Vall d'Hebron Institut d'Oncologia) ; Rodon, Jordi (Vall d'Hebron Institut d'Oncologia) ; González-Cao, María (Quirón Dexeus University Hospital) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Felip, Enriqueta (Universitat Autònoma de Barcelona) ; Sahuquillo Barris, Juan (Universitat Autònoma de Barcelona) ; Berger, Michael F. (Memorial Sloan Kettering Cancer Center) ; Cortés, Javier (Universitat Autònoma de Barcelona) ; Reis-Filho, Jorge S. (Memorial Sloan Kettering Cancer Center) ; Seoane Suárez, Joan (Universitat Autònoma de Barcelona)
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present in tumours and has been used to monitor tumour progression and response to treatments. [...]
2015 - 10.1038/ncomms9839
Nature communications, Vol. 6 (november 2015)  
2.
17 p, 1.3 MB Clinical implications of intratumor heterogeneity : challenges and opportunities / Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sesé, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Capdevila, Claudia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Aasen, Trond (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Diaz-Cano, Salvador J. (King's College Hospital NHS Foundation Trust) ; Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, and protein modifications that drive phenotypic selection in response to environmental pressures. [...]
2020 - 10.1007/s00109-020-01874-2
Journal of Molecular Medicine (Berlin, Germany), Vol. 98 (january 2020) , p. 161-177  
3.
30 p, 7.5 MB The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Sammut, S.J. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Ross, E.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Bashford-Rogers, R. (Department of Medicine. University of Cambridge) ; Greenstein, E. (Weizmann Institute of Science (Israel). Department of Immunology) ; Markus, H. (Mayo Clinic Center for Individualized Medicine) ; Morganella, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Teng, Y. (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ; Maruvka, Y. (Massachusetts General Hospital (Boston)) ; Pereira, B. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Rueda, O.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Chin, S.F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Contente-Cuomo, T. (Mayo Clinic Center for Individualized Medicine) ; Mayor, R. (Centro de Investigación Biomédica en Red de Cáncer) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Ali, H.R. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Cope, W. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Tiezzi, D. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Dariush, A. (Institute of Astronomy. University of Cambridge) ; Dias Amarante, T. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Reshef, D. (Weizmann Institute of Science (Israel). Department of Immunology) ; Ciriaco, 0000-0002-1151-554X (Hospital Universitari Vall d'Hebron) ; Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Vassiliou, G. (Wellcome Trust/MRC Cambridge Stem Cell Institute) ; Getz, G. (Massachusetts General Hospital (Boston)) ; Nik-Zainal, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Murtaza, M. (Mayo Clinic Center for Individualized Medicine) ; Friedman, N. (Weizmann Institute of Science (Israel). Department of Immunology) ; Markowetz, F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Caldas, C. (Cancer Research UK Cambridge Cancer Centre (Regne Unit)) ; Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10  
4.
14 p, 4.6 MB Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases / De Mattos-Arruda, Leticia (Memorial Sloan Kettering Cancer Center) ; Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ; Piscuoglio, Salvatore (Institute of Pathology, University Hospital Basel) ; Gonzalez-Cao, Maria (Grup Quirónsalud (Barcelona, Catalunya)) ; Lim, Raymond S. (Memorial Sloan Kettering Cancer Center) ; De Filippo, Maria R. (Memorial Sloan Kettering Cancer Center) ; Fusco, Nicola (Memorial Sloan Kettering Cancer Center) ; Schultheis, Anne M. (Memorial Sloan Kettering Cancer Center) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Macedo, Gabriel S. (Memorial Sloan Kettering Cancer Center) ; Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ; Gomez, Patricia (Vall d'Hebron Institut d'Oncologia) ; Teixidó, Cristina (Grup Quirónsalud (Barcelona, Catalunya)) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Tresserra Casas, Francesc (Grup Quirónsalud (Barcelona, Catalunya)) ; Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ; Cortés, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ; Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630  
5.
12 p, 2.2 MB MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Bottai, Giulia (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Di Tommaso, Luca (IRCCS Humanitas Clinical and Research Institute (Itàlia)) ; Giovannetti, Elisa (University of Pisa. Cancer Pharmacology Laboratory. AIRC Start-Up Unit (Italy)) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Losurdo, Agnese (IRCCS Humanitas Clinical and Research Institute (Itàlia). Division of Oncology and Hematology) ; Pérez-Garcia, José (Vall d'Hebron Institut d'Oncologia) ; Masci, Giovanna (IRCCS Humanitas Clinical and Research Institute (Itàlia). Division of Oncology and Hematology) ; Corsi, Fabio (University of Milan. Deparment of Clinical and Biomedical Sciences "Luigi Sacco" (Italy)) ; Cortés, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Calin, George A. (The University of Texas MD Anderson Cancer Center (USA)) ; Santarpia, Libero (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ; Universitat Autònoma de Barcelona
Patients with primary HER2-positive breast cancer benefit from HER2-targeted therapies. Nevertheless, a significant proportion of these patients die of disease progression due to mechanisms of drug resistance. [...]
2015 - 10.18632/oncotarget.5495
Oncotarget, Vol. 6, Num. 35 (October 2015) , p. 37269-37280  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.